AbbVie’s (ABBV) “Buy” Rating Reiterated at Guggenheim
AbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “buy” rating restated by Guggenheim in a research note issued to investors on Thursday,Benzinga reports. They presently have a $214.00 price objective on the stock. Guggenheim’s price objective would suggest a potential upside of 23.86% from the stock’s current price. A number of other research firms […]
More Stories
Vance Says Trump Admin Working to Facilitate Putin–Zelenskyy Talks
By Jacob Burg Vice President JD Vance said on Aug. 10 that the Trump administration is working to arrange talks...
Fed Official Says Latest Jobs Data Supports 3 Rate Cuts in 2025
By Jacob Burg Michelle Bowman, the Federal Reserve’s vice chair of supervision, on Aug. 9 said that recent job data...
Environmental Protection Agency Terminates Contracts With Unionized Employees
By Melanie Sun The Environmental Protection Agency (EPA) is ending all contracts with unionized employees, a union president said on...
Tom Brady Reacts to Patriots Statue Unveiling at Gillette Stadium
By Matthew Davis Tom Brady brought six Super Bowl championship trophies to the New England Patriots, and the organization has,...
Wall Street Review: IPOs and Tariff Relief Cause Stocks to Roar Back
By Panos Mourdoukoutas U.S. stocks roared back after retreating for a week. The S&P 500 Index edged closer to a...
Thousands Celebrate Their Love for Life on 2 Wheels at 85th Sturgis Rally
By Michael Clements STURGIS, S.D.—Clarence “Pappy” Hoel wanted to promote his Indian Motorcycle dealership in Sturgis, South Dakota, in 1936....